Sprint Bioscience AB - Asset Resilience Ratio

Latest as of September 2022: 77.81%

Sprint Bioscience AB (SPRINT) has an Asset Resilience Ratio of 77.81% as of September 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Sprint Bioscience AB strategic capital allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets

Skr26.73 Million

≈ $2.88 Million USD Cash + Short-term Investments

Total Assets

Skr34.35 Million

≈ $3.70 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2017)

This chart shows how Sprint Bioscience AB's Asset Resilience Ratio has changed over time. See Sprint Bioscience AB (SPRINT) balance sheet quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Sprint Bioscience AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SPRINT market cap overview.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Skr26.73 Million	77.81%
Short-term Investments	Skr0.00	0%
Total Liquid Assets	Skr26.73 Million	77.81%

Asset Resilience Insights

Very High Liquidity: Sprint Bioscience AB maintains exceptional liquid asset reserves at 77.81% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Sprint Bioscience AB Industry Peers by Asset Resilience Ratio

Compare Sprint Bioscience AB's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Spyre Therapeutics Inc. NASDAQ:SYRE	Biotechnology	84.34%
3SBio Inc F:83B	Biotechnology	10.64%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Jiangxi Fushine Pharmaceutical Co Ltd SHE:300497	Biotechnology	0.02%
Novavax Inc NASDAQ:NVAX	Biotechnology	53.87%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for Sprint Bioscience AB (2016–2017)

The table below shows the annual Asset Resilience Ratio data for Sprint Bioscience AB.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2017-12-31	4.17%	Skr1.48 Million ≈ $159.16K	Skr35.48 Million ≈ $3.82 Million	-43.50pp
2016-12-31	47.67%	Skr23.61 Million ≈ $2.54 Million	Skr49.52 Million ≈ $5.33 Million	--

pp = percentage points

About Sprint Bioscience AB

ST:SPRINT Sweden Biotechnology

Market Cap

$49.85 Million

Skr463.21 Million SEK

Market Cap Rank

#21964 Global

#408 in Sweden

Share Price

Skr4.39

Change (1 day)

+0.46%

52-Week Range

Skr0.45 - Skr4.39

All Time High

Skr47.75